Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838741 | 0.84 | PYGL (0.50) | CTSLCTSBCTSSGPR132MEN1 | |
| SCHEMBL5600846 | 0.76 | CHRNA7 (0.50) | MEN1RAB9AKMT2A | |
| SCHEMBL8504286 | 0.75 | HDAC6 (0.49) | CTSLCTSBCTSSGPR132LPAR1 | |
| SCHEMBL1837480 | 0.75 | MAOA (0.49) | NPC1RAB9A | |
| SCHEMBL1836676 | 0.72 | CTSK (0.61) | CTSLCTSBCTSSGPR132FAAH | |
| SCHEMBL1837320 | 0.72 | CNR2 (0.49) | CTSLCTSBCTSSNPC1RAB9A | |
| SCHEMBL15515607 | 0.72 | CTSL (0.58) | CTSLCTSBCTSS | |
| SCHEMBL1841973 | 0.71 | CNR2 (0.52) | MEN1NPC1RAB9AKMT2AFAAH | |
| SCHEMBL1837613 | 0.71 | TSHR (0.59) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1842072 | 0.71 | TSHR (0.69) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | disclosed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | DHODH 3356/4885CTSL 431/4885CTSB 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.